腹腔热灌注化疗在进展期胃癌术后的临床应用及疗效  

Clinical application and therapeutic effect of intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced gastric cancer

作　　者：王留伟[1] 

机构地区：[1]周口市中心医院普外一科,河南周口466000

出　　处：《临床研究》2017年第6期58-59,62,共3页Clinical Research

摘　　要：目的 探讨腹腔热灌注化疗在进展期胃癌术后的临床应用效果.方法 选择2011年8月至2013年3月在我院接受治疗的进展期胃癌术后患者96例作为研究对象,采用随机、双盲法将患者分为观察组和对照组,各48例.术后两组患者接受相同的全身辅助化疗,同时给予观察组患者腹腔热灌注化疗,随访3年,比较两组患者的近期疗效、远期生存率复发率及不良事件发生率.结果 治疗后,观察组患者的血清肿瘤标志物CEA、CA19-9、VEGF以及MMP水平明显低于对照组,差异有统计学意义（P＜0.05）;观察组3年生存率（68.75%）高于对照组（37.50%）,观察组复发率（6.25%）低于对照组（27.08%）,差异均具有统计学意义（P＜0.05）;两组不良事件发生率比较,无统计学差异（P＞0.05）.结论 腹腔热灌注化疗是提高进展期胃癌术后患者治疗质量的有效途径,可减少患者复发率,提高患者生存率,值得临床推广.Objective To explore the clinical effect of intraperitoneal hyperthermic perfusion chemotherapy in patients with advanced gastric cancer. Methods From August 2011 to March 2013, a total of 96 patients with advanced gastric cancer treated in our hospital were divided into observation group and control group by the random and double blind method with 48 cases in each group. The patients in the two groups were given the same systemic adjuvant chemotherapy after surgery, while the observation group were given intraperitoneal hyperthermic perfusion chemotherapy at the same time, all the pa- tients were followed up for three years. The recent efficacy, long-term survival rate, recurrence rate and incidence of adverse events of the two groups were compared. Results The serum markers levels of CEA, CA19-9, VEGF and MMP in the obser- vation group were significantly lower than those in the control group （P〈0.05）. The 3 year survival rate of the observation group （68.75%） was higher than that of the control group （37.50%）, the recurrence rate of the observation group （6.25%） was lower than that of the control group （27.08%）, the differences were statistically significant （P〈0.05）. There was no significant difference in the incidence of adverse events between the two groups. Conclusion Intraperitoneal hyperthermic perfusion chemotherapy is an effective method to improve the quality of postoperative patients with advanced gastric cancer, it can re- duce recurrence rate and improve the survival rate of patients, which is worthy of clinical promotion.

关 键 词：腹腔热灌注化疗 进展期 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]